# CRVS catalysts: Corvus Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/crvs/catalysts

> Corvus Pharmaceuticals, Inc. (CRVS) has 7 upcoming catalysts. The next is the soquelitinib interim data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CRVS?

Corvus Pharmaceuticals, Inc. (CRVS) has 7 upcoming catalysts. The next is the soquelitinib interim data readout, 1H 2027. Press release filed with the SEC (EX-99): "Initial data from the trial is anticipated in the 1H 2027." [Calendar and source filings](https://sec-api.dev/companies/crvs/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001171843-26-007175, https://www.sec.gov/Archives/edgar/data/1626971/000117184326007175/exh_991.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/crvs/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Corvus Pharmaceuticals, Inc. |
| Ticker | CRVS (Nasdaq) |
| SEC CIK | 1626971 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/crvs |

## Cash runway

Cash $202.9M as of 2026-09-30; quarterly burn $12.2M; about 49.8 months of runway at that rate (XBRL company facts, accession 0001104659-26-123317).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2024 | [Soquelitinib trial start](https://sec-api.dev/pdufa/soquelitinib) | CRVS | moderate to severe atopic dermatitis | completed | "In April 2024, we initiated a randomized, double-blind, placebo-controlled Phase 1 clinical trial with soquelitinib in patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic therapy." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1626971/000110465926123317/crvs-20260930x10q.htm)) |
| November 12, 2024 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184324006284/exh_991.htm)) |
| Dec 2024 | [Soquelitinib interim data readout](https://sec-api.dev/pdufa/soquelitinib) | CRVS |  | scheduled | "Corvus plans to announce interim data from the Phase 1 clinical trial in December 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184324006284/exh_991.htm)) |
| March 25, 2025 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184325001689/exh_991.htm)) |
| May 2025 | [Corvus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | scheduled | "We plan to report topline results from Cohorts 1, 2 and 3 in May 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1626971/000155837025003621/crvs-20241231x10k.htm)) |
| May 8, 2025 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184325002981/exh_991.htm)) |
| June 5, 2025 | [Soquelitinib interim data readout](https://sec-api.dev/pdufa/soquelitinib) | CRVS |  | scheduled | "Dr. Miller will highlight the new interim data in a presentation at the Jefferies Global Healthcare Conference, which is scheduled for 9:20 am ET / 6:20 am PT on Thursday, June 5, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184325003661/exh_991.htm)) |
| August 7, 2025 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184325005180/exh_991.htm)) |
| November 4, 2025 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184325006973/exh_991.htm)) |
| Q1 2026 | [Soquelitinib trial start](https://sec-api.dev/pdufa/soquelitinib) | CRVS | moderate to severe atopic dermatitis | scheduled | "Based on these positive results, the Company plans to initiate a Phase 2 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis that have failed at least one prior topical or systemic therapy in the first quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1626971/000110465926004795/tm263501d4_8k.htm)) |
| Mar 2026 | [Soquelitinib trial start](https://sec-api.dev/pdufa/soquelitinib) | CRVS | atopic dermatitis | completed | "In March 2026, we initiated a Phase 2 clinical trial of soquelitinib for the treatment of atopic dermatitis." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1626971/000110465926123317/crvs-20260930x10q.htm)) |
| March 12, 2026 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184326001526/exh_991.htm)) |
| May 7, 2026 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184326003154/exh_991.htm)) |
| August 6, 2026 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184326005317/exh_991.htm)) |
| Sep 2026 | [Soquelitinib trial start](https://sec-api.dev/pdufa/soquelitinib) | CRVS | moderate to severe hidradenitis suppurativa | completed | "In September 2026, we initiated a Phase 1b clinical trial with soquelitinib in patients with moderate to severe hidradenitis suppurativa." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1626971/000110465926123317/crvs-20260930x10q.htm)) |
| November 5, 2026 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184326007175/exh_991.htm)) |
| 1H 2027 | [Soquelitinib interim data readout](https://sec-api.dev/pdufa/soquelitinib) | CRVS |  | scheduled | "Initial data from the trial is anticipated in the 1H 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184326007175/exh_991.htm)) |
| Q1 2027 | [Soquelitinib trial start](https://sec-api.dev/pdufa/soquelitinib) | CRVS | asthma | scheduled | "Corvus plans to initiate a Phase 2 trial evaluating soquelitinib in patients with asthma, by Q1 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184326007175/exh_991.htm)) |
| Mar 2027 | [Soquelitinib topline data readout](https://sec-api.dev/pdufa/soquelitinib) | CRVS |  | scheduled | "Angel Pharmaceuticals completes enrollment in cohort 1 of Phase 1b/2 atopic dermatitis trial; topline data anticipated in March 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184326007175/exh_991.htm)) |
| June 2027 | [Soquelitinib primary completion](https://sec-api.dev/pdufa/soquelitinib) | CRVS | Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema | scheduled | "NCT07441395 (Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Corvus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07441395)) |
| Jun to Sep 2027 | [Soquelitinib topline data readout](https://sec-api.dev/pdufa/soquelitinib) | CRVS | Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema | scheduled | "NCT07441395 (Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Corvus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07441395)) |
| November 2027 | [Soquelitinib primary completion](https://sec-api.dev/pdufa/soquelitinib) | CRVS |  | scheduled | "NCT06561048 (Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Corvus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06561048)) |
| Nov 2027 to Feb 2028 | [Soquelitinib topline data readout](https://sec-api.dev/pdufa/soquelitinib) | CRVS |  | scheduled | "NCT06561048 (Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Corvus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06561048)) |

## Drugs

- [Soquelitinib](https://sec-api.dev/pdufa/soquelitinib): moderate to severe atopic dermatitis, atopic dermatitis, moderate to severe hidradenitis suppurativa, asthma, Peripheral T-Cell Lymphoma, Not Otherwise Specified

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/crvs/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CRVS catalysts: Corvus Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/crvs/catalysts

```bibtex
@misc{secapidev_companies_crvs_catalysts_20261116,
  title        = {CRVS catalysts: Corvus Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/crvs/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_crvs_catalysts_20261116","title":"CRVS catalysts: Corvus Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/crvs/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
